Zola-cel (BMS-986353)

BMS-986353 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Zola-cel (BMS-986353), covering 2026-03-05 to 2026-03-05. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis [Phase 3]

See pricing